>>Signaling Pathways>> Others>>Desoxycorticosterone pivalate

Desoxycorticosterone pivalate

Catalog No.GC38904

데속시코르티코스테론 피발레이트(DOCP)는 무기질 코르티코이드 호르몬이며 데속시코르티코스테론의 유사체입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Desoxycorticosterone pivalate Chemical Structure

Cas No.: 808-48-0

Size 가격 재고 수량
5mg
US$121.00
재고 있음
10mg
US$195.00
재고 있음
25mg
US$389.00
재고 있음
50mg Please Inquire Please Inquire
100mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism[1][2].

A starting dosage of 1.5 mg/kg Desoxycorticosterone pivalate (DOCP) is effective in controlling clinical signs and serum electrolyte concentrations in the majority of dogs with PH. An additional dose reduction often is needed to maintain an injection interval of 28-30 days. Young and growing animals seem to need higher dosages[1].

[1]. Sieber-Ruckstuhl NS, et al. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019 May;33(3):1266-1271. [2]. Masticatory Muscle Myositis: Pathogenesis, Diagnosis, and Treatment.

리뷰

Review for Desoxycorticosterone pivalate

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Desoxycorticosterone pivalate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.